AB3A Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - Sarepta Therapeutics Inc

Watchlist Manager

Watchlist

Price: 18.185 EUR Market Closed

Market Cap: €1.1B

S	Sarepta Therapeutics Inc XBER:AB3A	US
C	C&C Group PLC F:GCC	IE
E	enCore Energy Corp XMUN:6TU	US
D	DIC Asset AG XBER:DIC	DE
L	LY Corp XMUN:YOJ	JP
H	HydroGraph Clean Power Inc F:M98	CA

Profitability Summary

Sarepta Therapeutics Inc's profitability score is Hidden . We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin

70%

Strong 3Y Average Gross Margin

82%

Declining Gross Margin

86% > 70%

Negative Operating Margin

-1%

Negative 3Y Average Operating Margin

-11%

Operating Margin is Increasing

-51% > -1%

Low Net Margin

Negative 3Y Average Net Margin

-19%

Net Margin is Increasing

-90% > 3%

Healthy Free Cash Flow Margin

Negative 3Y Average Free Cash Flow Margin

-30%

Free Cash Flow Margin is Increasing

-53% > 5%

Low ROE

Negative 3Y Average ROE

Negative 3Y Average ROIC

-11%

ROIC is Increasing

-48% > -2%

View All Checks

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin

70%

Strong 3Y Average Gross Margin

82%

Declining Gross Margin

86% > 70%

Negative Operating Margin

-1%

Negative 3Y Average Operating Margin

-11%

Operating Margin is Increasing

-51% > -1%